ClinicalTrials.gg
CompletedNCT01513590BOOST™Updated Mar 26, 2019Results posted

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes

A Phase 3 interventional study of insulin degludec/insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 49 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-26.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
394
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
35th of 70
394 · median 384
Started
2012
with 5 others
Phase 3
49 of 70
2 open now
Registered
26th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 35th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 26th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Asia and Europe. The aim of the trial is to compare the efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 (biphasic insulin aspart 30) in insulin naïve subjects with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 394 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  • Type 2 diabetes mellitus (diagnosed clinically) for at least 24 weeks prior to screening
  • Current treatment: metformin monotherapy or metformin in any combination with one of the following oral anti-diabetic drugs (OADs): insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitor, alpha-glucosidase inhibitors for at least 12 weeks prior to randomisation (Visit 2) with the minimum doses stated: - Metformin: alone or in combination (including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000 mg daily), - Insulin secretagogue (sulphonylurea or glinide): minimum half of the daily maximum dose according to local labelling, - DPP-IV inhibitor: minimum 100 mg daily or according to local labelling, - Alpha-glucosidase-inhibitors: minimum half of the daily maximum dose or maximum tolerated dose
  • Insulin naïve subject; allowed is: Previous short term insulin treatment up to 14 days
  • Insulin naïve subject; allowed is: Treatment during hospitalization or during gestational diabetes is allowed for periods longer than 14 days)
  • (glycosylated ) between 7.0-10.0 % (both inclusive) by central laboratory analysis
  • (BMI) below or equal to 40.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with thiazolidinediones (TZDs) or glucagon like peptide 1 (GLP-1) receptor agonists within 12 weeks prior to visit 1 (screening)
  • Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic , beta-blockers and MAO inhibitors
  • Anticipated significant lifestyle changes during the trial according to the discretion of the trial physician, e.g. shift work (including permanent night/evening shift workers), as well as highly variable eating habits
  • Cardiovascular disease, within the last 24 weeks prior to trial start, defined as: stroke; decompensated heart failure (New York Heart Association) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
  • Any disease or disorder, except for conditions associated with type 2 diabetes, which in the trial physician's opinion could interfere with the results of the trial
  • Previous participation in this trial. Participation is defined as randomised. Re-screening of screening failures is allowed only once within the limits of the recruitment period
  • Known or suspected to trial products or related products
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
394 participants (actual)

Study arms

  • Experimental
    IDegAsp BID

    Drug: insulin degludec/insulin aspart

  • Active comparator
    BIAsp 30 BID

    Drug: insulin degludec/insulin aspart

Interventions

  • Druginsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)

    Change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment.

    Time frame: Week 0, week 26

  2. Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or Minor Hypoglycaemic Episodes

    The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes, which is presented here. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.

    Time frame: Onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product

  3. Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes

    The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes, which is presented here. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product

  4. Change From Baseline in Body Weight

    Change from baseline in body weight after 26 weeks of treatment.

    Time frame: Week 0, week 26

  5. Responder for HbA1c (Below 7.0%) Without Severe and Minor Treatment Emergent Hypoglycaemic Episodes During the Last 12 Weeks of Treatment Including Only Subjects Exposed for at Least 12 Weeks

    Responder for HbA1c (\<7.0%) without severe and minor treatment emergent hypoglycaemic episodes during the last 12 weeks of treatment. Severe + minor hypoglycaemic episodes = confirmed hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Week 26

  6. Number of Treatment Emergent AEs (Adverse Events)

    A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.

    Time frame: Onset on or after the first day of exposure to investigational product and no later than 7 days after exposure to investigational product

08

Results

Posted Nov 20, 2015

Participant flow

The trial was conducted at 47 sites in 10 countries: Algeria (4), Bulgaria (7), Croatia (5), Czech Republic (4), Germany (5), Poland (5), Romania (5), Slovakia (3), Turkey (2), and Ukraine (7).

Participant flow — Overall Study
MilestoneIDegAsp BIDBIAsp 30 BID
Started197197
Exposed196195
Completed187184
Not completed1013
Withdrew: Adverse event23
Withdrew: Withdrawal criteria30
Withdrew: Unclassified510

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin)

Change from baseline in HbA1c after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · Percent (%) glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Percent (%) glycosylated haemoglobinIDegAsp BIDBIAsp 30 BID
Change From Baseline in HbA1c (Glycosylated Haemoglobin)-1.85 ± 0.97-1.73 ± 0.93
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LIDegAsp BIDBIAsp 30 BID
Change From Baseline in Fasting Plasma Glucose (FPG)-4.44 ± 2.97-3.03 ± 2.90
SecondaryNumber of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or Minor Hypoglycaemic Episodes

The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes, which is presented here. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.

Time frame:
Onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product
Reported as:
Number · episodes
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or Minor Hypoglycaemic Episodes
episodesIDegAsp BIDBIAsp 30 BID
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or Minor Hypoglycaemic Episodes60260
SecondaryNumber of Severe and Minor Treatment Emergent Hypoglycaemic Episodes

The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes, which is presented here. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product
Reported as:
Number · episodes
Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes
episodesIDegAsp BIDBIAsp 30 BID
Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes5531221
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgIDegAsp BIDBIAsp 30 BID
Change From Baseline in Body Weight2.8 ± 4.12.0 ± 4.3
SecondaryResponder for HbA1c (Below 7.0%) Without Severe and Minor Treatment Emergent Hypoglycaemic Episodes During the Last 12 Weeks of Treatment Including Only Subjects Exposed for at Least 12 Weeks

Responder for HbA1c (\<7.0%) without severe and minor treatment emergent hypoglycaemic episodes during the last 12 weeks of treatment. Severe + minor hypoglycaemic episodes = confirmed hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Week 26
Reported as:
Number · participants
Responder for HbA1c (Below 7.0%) Without Severe and Minor Treatment Emergent Hypoglycaemic Episodes During the Last 12 Weeks of Treatment Including Only Subjects Exposed for at Least 12 Weeks
participantsIDegAsp BIDBIAsp 30 BID
Responder for HbA1c (Below 7.0%) Without Severe and Minor Treatment Emergent Hypoglycaemic Episodes During the Last 12 Weeks of Treatment Including Only Subjects Exposed for at Least 12 Weeks7759
SecondaryNumber of Treatment Emergent AEs (Adverse Events)

A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.

Time frame:
Onset on or after the first day of exposure to investigational product and no later than 7 days after exposure to investigational product
Reported as:
Number · events
Number of Treatment Emergent AEs (Adverse Events)
eventsIDegAsp BIDBIAsp 30 BID
Events197137
Serious2012
Severe138
Moderate4527
Mild139102
Fatal22

Adverse events

Collected over From the first trial-related activity after the subject had signed the informed consent (Week -1) and until post-treatment follow-up period (Week 27).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegAsp BID—13/196 (6.6%)15/196 (7.7%)
BIAsp 30 BID—10/195 (5.1%)7/195 (3.6%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventIDegAsp BIDBIAsp 30 BID
Myocardial ischaemiaCardiac disorders0/1962/195
HypoglycaemiaMetabolism and nutrition disorders2/1961/195
Cardiac failureCardiac disorders0/1961/195
Coronary artery insufficiencyCardiac disorders0/1961/195
Deafness neurosensoryEar and labyrinth disorders0/1961/195
Optic ischaemic neuropathyEye disorders0/1961/195
Non-cardiac chest painGeneral disorders0/1961/195
Peritonsillar abscessInfections and infestations0/1961/195
Foot fractureInjury, poisoning and procedural complications0/1961/195
Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1961/195
Most frequent other events
Most frequent other events
EventIDegAsp BIDBIAsp 30 BID
NasopharyngitisInfections and infestations15/1967/195

Baseline characteristics

Age, Continuous
Age, Continuous(years)IDegAsp BIDBIAsp 30 BIDTotal
Mean59.0 ± 9.558.8 ± 8.458.9 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)IDegAsp BIDBIAsp 30 BIDTotal
Female9596191
Male102101203
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(Percent (%) glycosylated haemoglobin)IDegAsp BIDBIAsp 30 BIDTotal
Mean8.5 ± 0.88.3 ± 0.78.4 ± 0.8
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDegAsp BIDBIAsp 30 BIDTotal
Mean10.5 ± 2.410.0 ± 2.310.2 ± 2.3
Body Weight
Body Weight(kg)IDegAsp BIDBIAsp 30 BIDTotal
Mean88.0 ± 15.088.5 ± 14.988.2 ± 14.9
09

Study locations

49 sites
  • Novo Nordisk Investigational Site
    Algiers, 16000, Algeria
  • Novo Nordisk Investigational Site
    Oran, 31000, Algeria
  • Novo Nordisk Investigational Site
    Setif, 19000, Algeria
  • Novo Nordisk Investigational Site
    Haskovo, 6300, Bulgaria
  • Novo Nordisk Investigational Site
    Lukovit, 5770, Bulgaria
  • Novo Nordisk Investigational Site
    Plovdiv, 4002, Bulgaria
  • Novo Nordisk Investigational Site
    Ruse, 7000, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1233, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1431, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1606, Bulgaria
  • Novo Nordisk Investigational Site
    Karlovac, 47000, Croatia
  • Novo Nordisk Investigational Site
    Osijek, 31 000, Croatia
  • Novo Nordisk Investigational Site
    Rijeka, 51 000, Croatia
  • Novo Nordisk Investigational Site
    Zadar, 23000, Croatia
  • Novo Nordisk Investigational Site
    Zagreb, 10000, Croatia
  • Novo Nordisk Investigational Site
    Brno, 65691, Czechia
  • Novo Nordisk Investigational Site
    Hradec Kralove, 50005, Czechia
  • Novo Nordisk Investigational Site
    Praha 10, 100 00, Czechia
  • Novo Nordisk Investigational Site
    Praha, 128 08, Czechia
  • Novo Nordisk Investigational Site
    Bochum, 44869, Germany
  • Novo Nordisk Investigational Site
    Hohenmölsen, 06679, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    Saint Ingbert-Oberwürzbach, 66386, Germany
  • Novo Nordisk Investigational Site
    Völklingen, 66333, Germany
  • Novo Nordisk Investigational Site
    Wangen, 88239, Germany
  • Novo Nordisk Investigational Site
    Bialystok, 15-445, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20-044, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20-538, Poland
  • Novo Nordisk Investigational Site
    Mazowieckie, 09-400, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 02-507, Poland
  • Novo Nordisk Investigational Site
    Oradea, Bihor 410469, Romania
  • Novo Nordisk Investigational Site
    Bucharest, 020614, Romania
  • Novo Nordisk Investigational Site
    Buzau, 120203, Romania
  • Novo Nordisk Investigational Site
    Galati, 800578, Romania
  • Novo Nordisk Investigational Site
    Sibiu, 550176, Romania
  • Novo Nordisk Investigational Site
    Bratislava, 821 02, Slovakia
  • Novo Nordisk Investigational Site
    Kosice, 040 01, Slovakia
  • Novo Nordisk Investigational Site
    Antalya, 07058, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34096, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34890, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, Turkey
  • Novo Nordisk Investigational Site
    Kocaeli, 41380, Turkey
  • Novo Nordisk Investigational Site
    Dnipro, 49023, Ukraine
  • Novo Nordisk Investigational Site
    Kyiv, 04114, Ukraine
  • Novo Nordisk Investigational Site
    Lviv, 79010, Ukraine
  • Novo Nordisk Investigational Site
    Poltava, 36003, Ukraine
  • Novo Nordisk Investigational Site
    Poltava, 36011, Ukraine
  • Novo Nordisk Investigational Site
    Vinnytsia, 21010, Ukraine
  • Novo Nordisk Investigational Site
    Zhytomyr, 10002, Ukraine
10

References and documents

Publications

  • Franek E, Haluzik M, Canecki Varzic S, Sargin M, Macura S, Zacho J, Christiansen JS. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes. Diabet Med. 2016 Apr;33(4):497-505. doi: 10.1111/dme.12982. Epub 2015 Nov 17. PubMed 26435365 ↗
  • Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes. J Diabetes. 2016 Sep;8(5):720-8. doi: 10.1111/1753-0407.12355. Epub 2016 Mar 6. PubMed 26612062 ↗
  • Haluzik M, Fulcher G, Pieber TR, Bardtrum L, Tutkunkardas D, Rodbard HW. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes Obes Metab. 2018 Jul;20(7):1585-1592. doi: 10.1111/dom.13261. Epub 2018 Mar 25. PubMed 29451706 ↗
  • Yang W, Akhtar S, Franek E, Haluzik M, Hirose T, Kalyanam B, Kar S, Wu T, Gogas Yavuz D, Unnikrishnan AG. Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes Ther. 2022 Feb;13(2):311-323. doi: 10.1007/s13300-021-01196-7. Epub 2022 Jan 19. PubMed 35044568 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Nov 2012, 10 months.

Results were first posted in Nov 2015, 3 years after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2012
First posted
Jan 20, 2012
StartActual
Jan 16, 2012
Primary completionActual
Nov 19, 2012
CompletionActual
Nov 19, 2012
Results first posted
Nov 20, 2015
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01513590
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Jan 16, 2012
Primary completion
Nov 19, 2012
Completion
Nov 19, 2012
Results posted
Nov 20, 2015
Last update
Mar 26, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion